These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24966191)

  • 1. Sex-based biology and the rational design of influenza vaccination strategies.
    Klein SL; Pekosz A
    J Infect Dis; 2014 Jul; 209 Suppl 3(Suppl 3):S114-9. PubMed ID: 24966191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex and gender differences in adverse events following influenza and COVID-19 vaccination.
    Yin A; Wang N; Shea PJ; Rosser EN; Kuo H; Shapiro JR; Fenstermacher KZJ; Pekosz A; Rothman RE; Klein SL; Morgan R
    Biol Sex Differ; 2024 Jun; 15(1):50. PubMed ID: 38890702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-based differences in immune function and responses to vaccination.
    Klein SL; Marriott I; Fish EN
    Trans R Soc Trop Med Hyg; 2015 Jan; 109(1):9-15. PubMed ID: 25573105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sex on responses to influenza vaccines.
    Denly L
    Hum Vaccin Immunother; 2021 May; 17(5):1396-1402. PubMed ID: 33180651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? - A systematic review.
    Tadount F; Doyon-Plourde P; Rafferty E; MacDonald S; Sadarangani M; Quach C
    Vaccine; 2020 Jan; 38(3):444-459. PubMed ID: 31711676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial.
    Li YP; Li W; Liang XF; Liu Y; Huang XC; Li CG; Li RC; Wang JZ; Wang HQ; Yin WD
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1297-307. PubMed ID: 23134570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-specific patterns of gene expression following influenza vaccination.
    Wen F; Guo J; Li Z; Huang S
    Sci Rep; 2018 Sep; 8(1):13517. PubMed ID: 30202120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
    Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
    Front Immunol; 2018; 9():3103. PubMed ID: 30761157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.
    Duval X; Caplanusi A; Laurichesse H; Deplanque D; Loulergue P; Vaman T; Launay O; Gillard P
    BMC Infect Dis; 2012 Jul; 12():162. PubMed ID: 22824474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.